# CB-012 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/cb-012

> CB-012, sponsored by Caribou Biosciences, Inc. (CRBU): 1 recorded catalyst.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | CB-012 |
| Codes | CB-012 |
| Sponsor | Caribou Biosciences, Inc. (CRBU) https://sec-api.dev/companies/crbu/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | fast track, orphan |

## Timeline

### February 13, 2024: trial start

- Status: completed. Date confidence: exact. Stage: 1.
- First seen 2025-03-10, last confirmed 2026-03-05.
- SEC Form 10-K (accession 0001619856-26-000008): "The relevant time period commenced on February 13, 2024, when the first patient was dosed with CB-012 in our AMpLify phase 1 clinical trial, and would have ended upon the earlier of the third anniversary from the approval of our biologics license application ("BLA") by the FDA or 10 years from February 13, 2024." https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm
- SEC Form 10-K (accession 0001619856-25-000015): "The relevant time period commenced on February 13, 2024, when the first patient was dosed with our anti-CLL-1 product candidate (CB-012) in our AMpLify phase 1 clinical trial and ends upon the earlier of the third anniversary of approval of our biologics license application ("BLA") by the FDA or 10 years from February 13, 2024." https://www.sec.gov/Archives/edgar/data/1619856/000161985625000015/crbu-20241231.htm
- SEC Form 10-K (accession 0001619856-25-000015): "The relevant time period commenced on February 13, 2024, when the first patient was dosed with our anti- C-type lectin-like molecule-1 ("CLL-1") product candidate (CB-012) in our AMpLify phase 1 clinical trial, and ends upon the earlier of the third anniversary of approval of our biologics license application ("BLA") by the U.S. Food and Drug Administration ("FDA") or 10 years from February 13, 2024." https://www.sec.gov/Archives/edgar/data/1619856/000161985625000015/crbu-20241231.htm
- SEC Form 10-K (accession 0001619856-25-000015): "The relevant time period commenced on February 13, 2024, when the first patient was dosed with our anti-CLL-1 product candidate (CB-012) in our AMpLify phase 1 clinical trial, and ends upon the earlier of the third anniversary from the approval of our biologics license application ("BLA") by the FDA or 10 years from February 13, 2024." https://www.sec.gov/Archives/edgar/data/1619856/000161985625000015/crbu-20241231.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/cb-012.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CB-012 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/cb-012

```bibtex
@misc{secapidev_pdufa_cb_012_20261116,
  title        = {CB-012 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/cb-012}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_cb_012_20261116","title":"CB-012 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/cb-012","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
